IPHC is generally used after surgical removal of as much cancer as possible (debulking), which may include the removal of all involved peritoneal areas. Evidence supports a benefit in certain cases of ovarian cancer. Evidence is insufficient as of 2020 to support its use in primary advanced epithelial ovarian, fallopian tube or primary peritoneal carcinoma, recurrent ovarian cancer, peritoneal colorectal carcinomatosis, gastric peritoneal carcinomatosis, malignant peritoneal mesothelioma, or disseminated mucinous neoplasm of the appendix. These procedures can be 8–10 hours long and carry a significant rate of complications. The chest counterpart of<unk>  is the<unk>  intrathoracic chemotherapy (HITOC). Chemotherapy agents Various chemotherapies are used and there is no clear consensus on which drugs should be used. Mitomycin C and oxaliplatin are the most commonly used agent for colorectal cancer, while cisplatin is used in ovarian cancer.
Hyperthermic intraperitoneal chemotherapy
Transcatheter arterial chemoembolization
Sequential high-dose chemotherapy
Dose-dense chemotherapy
Continuous hyperthermic peritoneal perfusion
Peritoneovenous shunt
Multisystemic therapy
Induction chemotherapy